InvestorsHub Logo
Followers 58
Posts 10128
Boards Moderated 1
Alias Born 09/21/2016

Re: Jonjones325 post# 167919

Saturday, 10/06/2018 2:40:24 PM

Saturday, October 06, 2018 2:40:24 PM

Post# of 461438

Hopefully, the ctad clearly lays out their rationale for the trial parameters. Hopefully it will answer more questions than it will create



Guys, none of us has a crystal ball and yes, this rodeo ride gets old. But, this time is different, IMO. The Amyloid causal Thesis path is just about done. P.M. is the best way from here. Any known science alternatives to AVXL are thin to none. This says to me that the dynamics are set to trigger on anything that looks real. And, if nothing else A2-73 looks real. Trouble is the trial n is low, yes, we know.

Considering the scope of AD WW and associated systemic international trauma, it will not take much to set of a big reaction. As Xena says, if strong evidence is presented for ongoing patient sleep patterns or other quality of life RWE is shown then it will help. I do agree that some kind of movement on a partnership would help a lot. IMO, BIIB is positioned to get involved w/AVXL and IMO, it will not take much to get them linked in.

Stay tuned, I expect news before the Barcelona show and tell.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News